Johnson & Johnson (NYSE:JNJ) Shares Bought by Annex Advisory Services LLC

Annex Advisory Services LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 5.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,438 shares of the company’s stock after purchasing an additional 1,735 shares during the period. Annex Advisory Services LLC’s holdings in Johnson & Johnson were worth $5,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. MRP Capital Investments LLC raised its position in Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after purchasing an additional 65 shares in the last quarter. Syverson Strege & Co increased its holdings in shares of Johnson & Johnson by 4.9% in the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after acquiring an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management increased its holdings in shares of Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock valued at $301,000 after acquiring an additional 66 shares during the last quarter. Denali Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.3% in the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock valued at $742,000 after acquiring an additional 67 shares during the last quarter. Finally, Sage Mountain Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock valued at $2,106,000 after acquiring an additional 67 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JNJ. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Wall Street Zen downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $153.39 on Thursday. The firm has a market capitalization of $369.07 billion, a P/E ratio of 23.07, a PEG ratio of 2.56 and a beta of 0.42. The stock has a fifty day moving average price of $153.81 and a 200 day moving average price of $153.67. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.